➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKinsey
Baxter
Merck
Medtronic

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: RE39916

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE39916
Title:Compounds that modulate PPAR activity and methods for their preparation
Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
Inventor(s): Auerbach; Bruce J. (Ann Arbor, MI), Bratton; Larry D. (Whitmore Lake, MI), Filzen; Gary (Ann Arbor, MI), Geyer; Andrew G. (Novi, MI), Trivedi; Bharat K. (Farmington Hills, MI), Unangst; Paul C. (Ann Arbor, MI)
Assignee: Warner Lambert Company (Morris Plains, NJ)
Application Number:11/288,022
Patent Claims:1. A compund of formula (I): ##STR00374## and pharmaceutically acceptable salts thereof, wherein: X.sup.0 and S; X.sup.1 is absent; O, S, --CH.sub.2--, --CH.sub.2--CH.sub.2--, or --CH.dbd.CH--; Ar.sup.1 and Ar.sup.2 are each independently unsubstituted or substituted phenyl or pyridinyl; ##STR00375## is absent; R.sup.1 and R.sup.2 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; R.sup.3 and R.sup.4 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; provided that at least one of R.sub.1-R.sub.4 is H, lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; m is 0 to 5; q is 0 to 1; and r is 0 to 1..].

.[.2. The compund of claim 1, wherein X.sup.1 is absent or 0; Ar.sup.1 and Ar.sup.2 are each independently unsubstituted or substituted phenyl or pyridinyl; R.sup.1 is hydrogen; R.sup.2 is lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; R.sup.3 is lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; R.sup.4 is hydrogen, lower alkyl, lower alkoxy, haloalkyl, --O--CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; m is 0 to 5; q is 1; and r is 0 to 1..].

.[.3. The compund of claim 1, wherein X.sup.1 is absent; Ar.sup.1 is phenyl; Ar.sup.2 is substituted phenyl or pyridinyl; R.sup.1 is hydrogen; R.sup.2 is lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.mCF.sub.3, --OH or --SH; R.sup.3 is lower alkyl or haloalkyl; R.sup.4 is hydrogen; m is 0 to 5; q is 1; and r is 0..].

.[.4. The compund of claim 1, wherein X.sup.1 is absent or 0; Ar.sup.1 is phenyl; Ar.sup.2 is substituted phenyl; R.sup.1 is hydrogen; R.sup.2 is lower alkoxy; R.sup.3 is lower alkyl; R.sup.4 is hydrogen; q is 1; and r is 0 to 1..].

.[.5. The compund of claim 1, wherein X.sup.1 is absent or 0; Ar.sup.1 is phenyl; Ar.sup.2 is substituted phenyl; R.sup.1 is hydrogen; R.sup.2 is methoxy; R.sup.3 is methyl; R.sup.4 is hydrogen; q is 1; and r is 0 to 1..].

.[.6. The compound of claim 1, wherein q is 1..].

.[.7. The compound of claim 1, wherein Ar.sup.1 is substituted or unsubstituted phenyl..].

.[.8. The compound of claim 1, wherein Ar.sup.2 is 4-trifluoromethylphenyl..].

.[.9. The compound of claim 1, wherein: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are selected from hydrogen, alkyl, or alkoxy..].

.[.10. The compound of claim 1, wherein: R.sup.2 and R.sup.3 are hydrogen; and R.sup.1 and R.sup.4 are alkyl or alkoxy..].

.[.11. The compound of claim 1, wherein: R.sup.1 is alkyl; R.sup.2 and R.sup.3 are hydrogen; and R.sup.4 is alkoxy..].

.[.12. The compound of claim 1, wherein: R.sup.1 is methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl; R.sup.2 and R.sup.3 are hydrogen; and R.sup.4 is methyoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, or isobutoxy..].

.[.13. A compound selected from: [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methylphenoxy]-acetic acid; [5-Methoxy-2-methyl-4-(4'-trifluoromethyl-biphenyl-4-ylmethylsulfanyl)-ph- enoxy]-acetic acid; [4-(2',4'-Dichloro-biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenox- y]-acetic acid; [5-Methoxy-2-methyl-4-(3'-trifluoromethyl-biphenyl-4-ylmethylsulfanyl)-ph- enoxy]-acetic acid; [4-(4'-Fluoro-biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-ac- etic acid; [5-Methoxy-2-methyl-4-[4-(4-trifluoromethyl-benzyloxy)-benzylsulfanyl]-ph- enoxy]-acetic acid; [5-Methoxy-2-methyl-4-(3'-trifluoromethoxy-biphenyl-3-ylmethylsulfanyl)-p- henoxy]-acetic acid; {{-Methoxy-2-methyl-4-[4-(5-trifluoromethyl-pyridin-2-yl)-benzylsulfanyl]- -phenoxy}-acetic acid; {5-Methoxy-2-methyl-4-[6-(4-trifluoromethyl-phenyl)-pyridin-3-ylmethylsul- fanyl]-phenoxy}-acetic acid; [3-Methoxy-4-(4'-trifluoromethyl-biphenyl-4-ylmethylsulfanyl)-phenoxy]-ac- etic acid; (4-{4-[2-(3-Fluoro-phenyl)-vinyl]benzylsulfanyl}-5-methoxy-2-methyl-pheno- xy)-acetic acid; [5-Methoxy-2-methyl-4-(3-methyl-4'-trifluoromethyl-biphenyl-4-ylmethylsul- fanyl)-phenoxy]-acetic acid; [5-Methoxy-2-methyl-4-(4'-trifluoromethyl-biphenyl-3-ylmethylsulfanyl)-ph- enoxy]-acetic acid; and pharmaceutically acceptable salts thereof..].

.[.14. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof admixed with a carrier, diluent, or excipient..].

15. A method of treating or controlling non-insulin dependent diabetes mellitus in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of .[.claim 1.]. .Iadd.formula (I): ##STR00376## or a pharmaceutically acceptable salt thereof wherein: X.sup.0 is S; X.sup.1 is absent, O, S, --CH.sub.2--, --CH.sub.2--CH.sub.2--, or --CH.dbd.CH; Ar.sup.1 and Ar.sup.2 are each independently unsubstituted or substituted phenyl or pyridinyl; ##STR00377## is absent; R.sup.1 and R.sup.2 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; R.sup.3 and R.sup.4 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3, provided that at least one of R.sub.1-R.sub.4 is H, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; m is 0 to 5; q is 0 to 1; and r is 0 to 1.Iaddend..

16. A method of treating or controlling obesity in a mammal comprising adminsitering to the mammal in need thereof a therapeutically effective amount of a compound of .[.claim 1.]. .Iadd.formula (I): ##STR00378## or a pharmaceutically acceptable salt thereof, wherein: X.sup.0 is S; X.sup.1 is absent, O, S, --CH.sub.2--, --CH.sub.2--CH.sub.2--, or --CH.dbd.CH; Ar.sup.1 and Ar.sup.2 are each independently unsubstituted or substituted phenyl or pyridinyl; ##STR00379## is absent; R.sup.1 and R.sup.2 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; R.sup.3 and R.sup.4 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3, provided that at least one of R.sub.1-R.sub.4 is H, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; m is 0 to 5; q is 0 to 1; and r is 0 to 1.Iaddend..

.[.17. A method of treating or controlling eating disorders in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1..].

.[.18. A method of supressing appetite in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1..].

.[.19. A method of modulating leptin levels in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1..].

.[.20. A method of treating or controlling hyperglycemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1..].

.[.21. A method of treating or controlling hyperinsulinemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1..].

.[.22. A method of treating a patient exhibiting glucose disorders associated with circulating glucocorticoids, growth hormone, catecholamines, glucagon, or parathyroid hormone, comprising administering to the patient a therapeutically effective amount of a compound of claim 1..].

.[.23. A method of treating non-insuline dependent diabetes mellitus in a patient comprising administering to the patient in need of treatment a composition according to claim 14..].

24. A method of treating metabolic syndrome in a patient comprising administering to the patient in need of treatment a composition .[.according to claim 14.]. .Iadd.comprising a compound of formula (I): ##STR00380## or a pharmaceutically acceptable salt thereof, wherein: X.sup.0 is S; X.sup.1 is absent, O, S, --CH.sub.2--, --CH.sub.2--CH.sub.2--, or --CH.dbd.CH; Ar.sup.1 and Ar.sup.2 are each independently unsubstituted or substituted phenyl or pyridinyl; ##STR00381## is absent; R.sup.1 and R.sup.2 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; R.sup.3 and R.sup.4 are selected from hydrogen, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3, provided that at least one of R.sub.1-R.sub.4 is H, lower alkyl, lower alkoxy, haloalkyl,--O--(CH.sub.2).sub.mCF.sub.3, halogen, nitro, cyano, --OH, --SH or --CF.sub.3; m is 0 to 5; q is 0 to 1; and r is 0 to 1; and a pharmacuetically acceptable carrier, diluent or vehicle.Iaddend..

Details for Patent RE39916

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Warner Lambert Company (Morris Plains, NJ) 2022-04-05 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Warner Lambert Company (Morris Plains, NJ) 2022-04-05 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Warner Lambert Company (Morris Plains, NJ) 2022-04-05 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Warner Lambert Company (Morris Plains, NJ) 2022-04-05 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
Dow
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.